The application of fluorescence techniques in meningioma surgery-a review by Dijkstra, Bianca M. et al.
 
 
 University of Groningen
The application of fluorescence techniques in meningioma surgery-a review





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Dijkstra, B. M., Jeltema, H-R. J. R., Kruijff, S., & Groen, R. J. M. (2019). The application of fluorescence
techniques in meningioma surgery-a review. Neurosurgical review, 42(4), 799-809.
https://doi.org/10.1007/s10143-018-01062-4
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
REVIEW
The application of fluorescence techniques in meningioma
surgery—a review
Bianca M. Dijkstra1 & Hanne-Rinck (J.R.) Jeltema1 & Schelto Kruijff2 & Rob J. M. Groen1
Received: 21 September 2018 /Revised: 11 November 2018 /Accepted: 23 November 2018
# The Author(s) 2018
Abstract
Surgical resections of meningiomas, the most common intracranial tumor in adults, can only be curative if radical resection is
achieved. Potentially, the extent of resection could be improved, especially in complex and/or high-grade meningiomas by
fluorescence-guided surgery using 5-aminolevulinic acid (5-ALA), indocyanine green (ICG), or fluorescein. This review aims
to summarize and evaluate these fluorescence-guided meningioma surgery techniques. PubMed and Embase were searched for
relevant articles. Additionally, we checked reference lists for further studies. Forty-eight articles were included in the final
analysis. 5-ALA fluoresced with varying sensitivity and selectivity in meningiomas and in invaded bone and dura mater.
Although ICG was mainly applied for video angiography, one report shows tumor fluorescence 18–28 h post-ICG injection.
Lastly, the use of fluorescein could aid in the identification of tumor remnants; however, detection of dural tail is highly
questionable. Fluorescence-guided meningioma surgery should be a reliable, highly specific, and sensitive technique. Despite
numerous studies reporting the use of fluorescent dyes, currently, there is no evidence that these tools improve the radical
resection rate and long-term recurrence-free outcome in meningioma surgery without neurological deficits. Evidence regarding
the effectiveness and increased safety of resection after the application of these fluorophores is currently lacking. Future research
should focus on the development of a meningioma-targeted, highly sensitive, and specific fluorophore.
Keywords Meningioma . Fluorescence-guided surgery . Intraoperative imaging . 5-Aminolevulinic acid . Fluorescein .
Indocyanine green
Introduction
Meningiomas are the most frequently occurring intracranial
tumors in adults, accounting for one third of cases [1]. They
are classified into three separate World Health Organization
(WHO) grades based on histology, mitotic index, and the
presence of brain invasion [2]. Although meningiomas are
mostly benign and slow growing, they compress surrounding
brain tissue and nerves. Depending on location and time
course, symptoms such as seizures, focal neurological deficits
(e.g., extremity weakness or visual changes), or (severe) men-
tal status changes can arise. Treatment is most effective when
complete surgical radical resection is achieved aiming to re-
move the complete tumor while preserving neurological func-
tion. Incomplete resection is a major risk factor for recurrence
[2]. Currently, differentiation between meningioma tumor in-
vasion in the dura mater or adjacent bone and reactive tissue is
limited. Chances of safe gross total resection without
compromising neurological outcome may decrease due to lo-
cation (such as the cerebellopontine angle), invasion of dura
and/or bone, and involvement of neurovascular structures.
Fluorescence-guided meningioma surgery may be a helpful
tool to increase the extent of resection, especially in patients
with complex meningiomas.
Introduced in 1948 by Moore et al, fluorescein was ap-
plied to visualize brain tumors [3]. Later, 5-aminolevulinic
acid (5-ALA) has been implemented in the field of neuro-
surgery, mainly in glioblastoma surgery [4]. Indocyanine
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green (ICG) has been utilized for video angiography main-
ly for neurovascular neurosurgery (aneurysms, arteriove-
nous malformation, and fistulas) [5]. More recently, these
dyes have been applied in meningioma resections.
This review aims to give a descriptive overview of the most
frequently applied intra-operative dyes (5-ALA, ICG, and
fluorescein) in meningioma surgery and evaluate their role
in terms of efficacy, additional extent of resection, and com-
plication rate.
Material and methods
PubMed and Embase were searched (search strategy in
Supplemental Table 1). There were no restrictions regarding
publication date; however, only full-text articles in English
were assessed. The latest search update was on the 10th of
July, 2018. No quality assessment was performed because the
quality of the reports appeared insufficient during full-text
screening of the articles.
Results
Literature search
The literature search revealed 427 articles. After duplicate
removal, each abstract (n = 314) was screened independently
by two authors (BMD and RJMG) and reference lists were
evaluated to identify additional relevant articles. In total, 88
full-text articles were assessed for eligibility. Of these, 48 ar-
ticles were included in the final analysis. We excluded review
articles, editorials, letters to editors containing no new exper-
imental data, author replies, and comments (Fig. 1).
Below, we will consecutively describe the reported use of
5-ALA, ICG, and fluorescein in meningioma surgery. More
specifically, the application of these fluorophores will be
reviewed separately in imaging of the tumor, adjacent
(invaded) dura mater, and bone. Additionally, other applica-
tions of these dyes will be summarized.
5-Aminolevulinic acid
After oral administration, 5-aminolevulinic acid (5-ALA)
causes the induction of protoporphyrin IX (PpIX), a natural
precursor of hemoglobin, which is normally converted to
heme by ferrochelatase. In tumor cells, ferrochelatase activity
is lower compared to normal tissue, and thus, PpIX accumu-
lates mostly in tumor cells. It is excited by wavelengths of
400 nm and emits wavelengths at 620–710 nm [6]. In neuro-
surgery, it has been approved for glioma surgery, where it
increased both the extent of resection and survival [6]. In
meningioma surgery, 5-ALA has been used off-label to detect
intracranial and spinal meningiomas. Its application has been
described in the detection of invasion of the dural tail and bone
as well (Tables 1 and 2).
Tumor imaging
Most publications report cases or case series evaluating fluo-
rescence status (intensity, homogeneity) in intracranial menin-
gioma [7–23]. In a recent review [33] and meta-analysis [34],
it appeared difficult to draw conclusions regarding the role of
5-ALA in meningioma surgery due to the experimental nature
of 5-ALA-guided meningioma surgery. Most importantly,
sensitivity and specificity rates were inconsistent between
studies, although remaining high with an overall sensitivity
of 92–98% and specificity of 95%. No correlation between
fluorescent intensity and WHO grade or histological subtype
became apparent and fluorescence was often heterogenic
[7–23, 33, 34]. These findings are similar to our own experi-
ence. By way of illustration, a 50-year-old male patient
underwent 5-ALA-assisted surgery of a recurrent grade I
(meningotheliomatous) meningioma. Bright violet homoge-
neous fluorescence was observed intraoperatively with an in-
homogeneous fluorescence pattern (Fig. 2).
Although 5-ALA has primarily been applied in intracranial
meningiomas, its use in spinal meningiomas has been of in-
terest as well. In two separate case reports, it allowed for the
discrimination between tumor tissue and scar tissue [24] or
normal tissue and residual tumor [25]. In another case series,
fluorescence was homogenous in ten patients (83%) and het-
erogeneous in two patients (17%) [26].
Dural imaging
Fluorescence status in the dural tail was observed in 103 sam-
ples. Only 30 samples (29%) were histologically analyzed. Of
these, six patients with histologically confirmed meningioma
invasion showed fluorescence in the dural tail (20%) [7, 19].
Unaffected dura mater did not fluoresce in 17 cases (57%)
[7–9, 12, 20]. Additionally, six affected dural tails (20%) did
not fluoresce [20, 23]. Lastly, Brokinkel et al [23] showed
PpIX formation of a non-fluorescent-invaded tail, using mass
spectrometry.
Bone imaging
Fluorescence status in bone flaps was determined in 129 sam-
ples in total [7, 8, 10, 14, 15, 20–22, 27, 28] with subsequent
histological evaluation in 114 samples (88%). Of these, 69
samples (61%) fluoresced and showed meningioma invasion
upon histological examination [7, 10, 14, 20, 22, 28]. Both
bright and weak fluorescence have been noted. In one report,
fluorescent hyperostotic bone showed involvement in all sam-
ples (n = 36) and non-fluorescent non-hyperostotic bone was
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unaffected in all samples (n = 5) [28]. Invaded bone did not
fluoresce in eight samples (7%) [14, 28]. Lastly, in 36 samples
(32%), absence of tumor cells in non-fluorescent bone was
confirmed [8, 27, 28].
Other applications
A handheld probe (minispectrometer) could detect fluores-
cence with 100% sensitivity in a spatial resolution of 1 mm2
in one patient harboring a skull base meningioma [11]. In
another report, sensitivity of the minispectrometer was 93%
(versus only 53% of surgical microscope), probably due to
close proximity of the light source to the tumor [31].
Additionally, the authors reported that they could better dis-
tinguish invaded dural tail from normal dura mater using the
probe [18, 29] and others claimed that they were able to dif-
ferentiate glioblastomas from meningiomas based on fluores-
cence intensity [30].
Red light excitation of PpIX increased penetration depth up
to 5 mm. Compared to blue light excitation, specificity and
sensitivity were lower, and fluorescence was weaker using red
light excitation. Additionally, in order to generate overlay
Fig. 1 Study flow diagram
Table 1 Types of trials of 5-ALA,
ICG, and fluorescein in
meningioma surgery research
Fluorophore Tumor imaging Dural imaging Bone imaging Other applications
5-ALA X X X Handheld probe, red light excitation
ICG X Video angiography
Fluorescein X X X Video angiography, confocal microscopy
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Chae et al. 2012 [13] 1 69 0 I n.a. 100 Yes Tumor
















Cornelius et al. 2014 [16] 31 58.7 65 I (61)
II (26)
III (13)
94 100 ND Tumor
Marbacher et al. 2014 [17] 110 ND ND I (85)
II (13)
III (2)
77% fluoresced ND Tumor






















































Eicker et al. 2013 [24] 8 64.6 100 I (100) 88 100 Yes Tumor (spinal)
Muroi et al. 2013 [25] 1 78 100 II n.a. 100 Yes Tumor (spinal)
Millesi et al. 2014 [26] 12 61.8 83 I (100) 100 100 Yes Tumor (spinal)
Cornelius et al. 2013 [27] 1 65 100 I ND ND ND Bone
Della Puppa et al. 2014 [28] 12 59.8 67 I (83)
II (17)
89 100 Yes Bone
Valdés et al. 2011 [29] 6 ND ND I
II
100 93 Yes Probe
Cornelius et al. 2017 [30] 5 ND ND I (100) ND ND ND Probe
Knipps et al. 2017 [31] 13 ND ND I (77)
II (23)
93 95 Yes Probe
Roberts et al. 2017 [32] 6 ND ND I (67)
II (17)
III (17)
ND ND Yes Red-light
excitation
Total 538 58.6 81 I (79.1)
II (15.9)
III (4.9)
*Only 18% histologically verified
n, number of relevant patients or samples; ND, not described
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images, this technique was not real-time. One meningioma
fluoresced using blue light excitation, but did not with red
light excitation [32].
Indocyanine green
ICGwas first approved for assessing hepatic and cardiac func-
tioning, and later in ophthalmology. The use of ICG in menin-
gioma surgery has only recently been explored, most frequent-
ly using ICG video angiography (ICG VA), visualizing the
vasculature and not the tumor itself. A summary of included
applications and articles has been listed in Tables 1 and 3.
Tumor imaging
One publication reported the Bsecond window technique^
where ICG was administered 18–28 h preoperatively.
Seventy-eight percent of cases showed tumor fluorescence.
Patients injected > 22 h prior to surgery demonstrated an in-
verse fluorescence pattern, i.e., healthy brain fluoresced
stronger than tumor. Sensitivity was high (96%), but specificity
was low (39%), possibly due to camera exposure settings [35].
Dural imaging
No reports have established the application of ICG for the
identification of meningioma invasion of the dural tail.
Bone imaging
No reports have established the application of ICG for the
identification of meningioma bone invasion.
Other applications
Transdural video angiography applies ICG VA to visualize cor-
tical veins, dural venous sinuses, and/or tumor boundaries prior
to dural opening in 46 patients [39–42, 45, 46]. It allowed for a
tailored dural opening without damaging underlying vascula-
ture and the possibility of assessing vessel patency and blood
flow (direction) [40–42, 45]. One group described the BEclipse
Fig. 2 Top panel shows gadolinium contrast-enhanced MRI scans of a
recurrent grade I meningioma in a 50-year-old male. Bottom panel
depicts intraoperative images after preoperative oral administration of 5-
ALA. MRI scans revealed a recurrent parietal meningioma (a, b).
Intraoperatively, the meningioma became visible using white light (c)
and after excitation with blue light, the meningioma showed bright violet,
inhomogeneous fluorescence (d)
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sign^ [43, 44], which occurs after coagulating feeding arteries,
dura mater, and middle meningeal arteries. It can be observed
transdurally: the meningioma appears as a shadow after ICG
injection due to reduced or absent blood flow, in contrast to
dura and adjacent normal brain. This sign was observed in eight
patients (40%) [43, 44]. According to the authors, absent (52%)
or reduced (8%) BEclipse sign^ was suggestive of intracranial
arterial supply to the tumor [43, 44].
Using arterial video angiography, patency of arteries
after manipulation for tumor resection was confirmed in
three patients [36]. Moreover, collateral arterial circulation
was demonstrated, with subsequent sacrifice of arteries
improving surgical resection without post-operative ische-
mia in 17 patients [36–38]. In total, 43% of 23 patients in
total showed benefit from ICG VA arterial imaging, as
judged by the surgeons through additional resection with-
out ischemia.
Venous video angiography has been applied in 97 patients.
According to the authors, the rate of resection was occasion-
ally increased by confirming occlusion of veins using ICGVA
in thrombosed veins [36, 40, 45, 47], identifying collateral
venous drainage with [36, 39, 48] or without [39] subsequent
venous sacrifice, and determining the relation of veins with
the tumor (draining versus collateral veins) [39, 42, 45].
Fluorescein
Fluorescein was first applied in 1948 for the identification of
several types of brain tumor types [3]. Later it was used in
ophthalmology for retinal imaging and more recently in neu-
rosurgery, mostly in glioblastoma surgery [49]. It has a peak
excitation at 490 nm and emission between 500 and 550 nm.
Fluorescein has been tried in meningioma surgery with and
without yellow 560 nm filter, and as a contrast agent in con-
focal microscopy. Reports show fluorescein imaging without
appropriate controls or histological confirmation, making the
evaluation of this technique extremely difficult. A summary of
fluorescein intraoperative imaging is given below and an over-
view is listed in Tables 1 and 4.
Tumor imaging
The use of fluorescein-guided surgery without a micro-
scope filter has been described in skull base [50–52] and
Table 3 Data of studies using ICG included in this review
Study n Age (mean) Sex (% female) WHO (%) Benefit* (%) Focus
Lee et al. 2017 [35] 18 55.2 72 I (83)
II (17)
n.a. Tumor




Kim et al. 2013 [37] 2 38.5 50 ND 100 Arterial VA
Rustemi et al. 2016 [38] 1 ND ND ND 100 Arterial VA














Nussbaum et al. 2012 [41] 2 62.5 50 ND 100 Transdural VA




Ueba et al. 2013 [43] 2 ND ND ND 100 Transdural VA
Ueba et al. 2013 [44] 23** 56.9 90 I (100) 44 Transdural VA






Hide et al. 2015 [46] 4 ND ND ND 100 Transdural VA
Khurana et al. 2010 [47] 5 44.6 80 ND 20 Venous VA
Ferroli et al. 2011 [48] 2 68.5 100 ND 100 Venous VA
Total*** 160 55.3 72.3 I (89.1)
II (10.9)
51.8
*Benefit of application shown in percentage
**Patient data of only ten patients has been described
***Valid percentages are shown
ND, not described; VA, video angiography
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convexity meningiomas [53]. Overlap of patients between
these studies occurs. Fluorescent signal appeared in the
meningioma 10 min after injection using a standard white
light microscope, with heightened contrast between menin-
giomas and cranial nerves. Digitally quantified pre- and
post-resection fluorescence showed statistical significant
difference [50–52]. Using a yellow 560 nm microscope
filter in 30 patients, homogeneous fluorescence occurred
in 88% of meningiomas and 12% showed heterogeneous
tumor fluorescence [54]. Furthermore, the authors reported
that the application of fluorescein did not significantly
change the surgical plan [54].
Dural imaging
One case series reported the identification of meningioma-
positive dural tail in five patients (100%) by fluorescein fluo-
rescence using a standard white light microscope [53].
Adjacent dura mater fluoresced in all cases (n = 25) applying
a yellow-560 nm filtered microscope in another study, al-
though this was not histologically confirmed [54].
Bone imaging
Bone involvement has not been described using fluorescein-
guided standard white light surgical microscopy. However, it
could be identified in five patients (20%) using filtered mi-
croscopy: bone fluorescence was observed in three bone flaps
and in two skull base meningiomas [54].
Other applications
Confocal microscopy could reveal histopathological details,
such as dense sheets, psammoma bodies, microscopic margin
between tumor and brain parenchyma, and dural invasion [55,
56]. Furthermore, WHO grade and meningioma subtype
could be determined correctly with high sensitivity and spec-
ificity [56, 57]. A high number of images were uninterpretable
due to blood or motion artifacts and histology was vaguer
compared to H&E sections [55–57].
Fluorescein video angiography at the end of resection was
successfully applied to evaluate vessel patency and feeding
and en passage vessels. The authors claim it was useful in
vessel preservation and prevention of morbidity; however,
no long-term follow-up was available [54].
Discussion
The main risk factor for meningioma recurrence is an incom-
plete resection. In order to improve extent of resection, the
ability to adequately identify tumor to normal tissue borders
should be enhanced. This may be possible through the appli-
cation of intraoperative fluorescence-guided surgery. In this
review, we evaluated the literature and summarized the intra-
operative use of 5-ALA, ICG, and fluorescein aiming to de-
termine the benefit of fluorescent guidance during meningio-
ma surgery in striving for a radical resection.
Current reports have major limitations. In this review, the
majority of included studies are case reports or series with
low level of evidence. Only a few report large(r) patient cohorts.
Table 4 Data of studies using fluorescein included in this review
Study n Age (mean) Sex (% female) WHO (%) Histol. verific. Focus
da Silva et al. 2010 [50]* 3 ND ND ND ND Tumor
da Silva et al. 2014 [51]* 12 ND ND ND ND Tumor
da Silva et al. 2014 [52]* 9 ND ND ND ND Tumor
da Silva et al. 2014 [53]* 5 57.6 60 I (80)
II (20)
Yes Tumor, dural tail
Akçakaya et al. 2017 [54] 30 48.9 80 I (90)
II (10)
Yes Tumor, dural tail, bone,
video angiography
Sanai et al. 2011 [55] 6 ND ND ND Yes Confocal microscopy
Eschbacher et al. 2012 [56] 24 ND ND I (83)
II (17)
Yes Confocal microscopy




Total 107 50.9 77.1 I (85.4)
II (13.5)
III (1.1)
*Overlap between reported patients occurs in these studies
ND, not described
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To date, most studies are only anecdotal without an adequate
study design: they cannot provide strong evidence and merely
reflect the surgeon’s observations, e.g., extent of resection or
additional safe resection. Only few reports are based on
(partially) standardized protocols, for example, noting fluores-
cence status of tumor, bone, dura mater, and adjacent healthy
tissue with at least documentation of neurological deficits and
post-operative MRIs determining rate of resection. Indeed, few
of the included studies followed a structured sampling ap-
proach. Thus, these outcome measures are often biased by the
investigator(s) and not readily comparable between patients,
even within the same study. Moreover, most studies are retro-
spective and no randomized controlled trials have been report-
ed. Most reports lack reliable patient data, such as basic patient
characteristics, histopathological data, and (long term) follow-
up. Consequently, currently, the level of evidence for the use of
fluorescence is low due to selection bias.
Reported follow-up time was mostly very limited (Bpost-
operative days,^ Bpost-operatively^) without long-term out-
come. Short-term outcomes were mostly positive: transient
or no neurological deficit and (in only a few reports) complete
resection on post-operative MRI. Long-term confirmation of
radical resection without neurological deficits could not be
determined, e.g., in terms of progression-free survival or re-
currence rates. These outcome variables are essential for the
evaluation of fluorescent techniques.
Furthermore, most studies used a dichotomous scoring sys-
tem to assess quality of fluorescence signal. Although this sys-
tem is easily reproducible, it is not applicable for all clinical
and/or experimental issues [58] and quantification of fluores-
cence intensity is flawed. A three- or five-level grading score
would be more appropriate for the objective recording of fluo-
rescence quality. Due to clinical applicability, the three-level
system would be the first choice [58], e.g., non-fluorescent
(1), minimal/moderate fluorescent (2), and highly fluorescent
(3). Additionally, quantifying fluorescence using an intraopera-
tive spectrometer enables the comparison of fluorescence inten-
sity in a more standardized fashion by measuring absolute fluo-
rescence levels. Although some studies applied in vivo spec-
trometry with quantitative analysis using an intraoperative
probe, the majority only performed a qualitative analysis.
Numerous drawbacks of presently applied dyes became
apparent in this review. Currently, no compelling evidence is
available regarding the benefit of fluorescence-guided menin-
gioma surgery. It might aid surgical resection in select cases
through detection of meningioma remnants or invasion or by
aiding in safe vascular sacrifice. Additionally, the investigated
fluorophores severely lack sensitivity and specificity to distin-
guish meningioma (infiltration) from healthy brain tissue.
Multiple studies applying 5-ALA show heterogenic meningi-
oma fluorescent patterns [12, 33] and emphasize the role of
homogenic fluorescence in complete surgical resection.
However, fluorescence homogeneity was not discussed in
most reports investigating any of the three investigated
fluorophores. Tumor margin determination was unreliable,
reducing the value of using these fluorophores. Moreover,
histological analysis of individual samples was almost never
or only partially reported, which diminishes the ability to cor-
relate fluorescence (intensity) with presence of meningioma
cells and severely limits the possibility of calculating sensitiv-
ity and specificity rates.
In tumor imaging, 5-ALA has high sensitivity and specific-
ity for meningioma tissue. However, fluorescence heterogene-
ity and the absence of correlation between fluorescence and
mitotic index remain relevant issues. Sensitivity is low(er) in
dural and bone invasion compared to the fluorescence results
obtained in the tumor itself. Recently, PpIX formation in a non-
fluorescent-invaded dural tail was confirmed using mass spec-
trometry. Although emphasizing the need for a more accurate
technique in fluorescence-guided meningioma surgery, this
technique is highly inefficient in clinical practice. Only one
study described imaging of the meningioma tumor using ICG
[54]. The imaging protocol should be improved to increase
sensitivity rates and tumor-to-background ratio. Other reports
apply video angiography for transdural, arterial, and/or venous
imaging, claiming the benefit for half of the patients, deter-
mined by surgeons personal (subjective) judgment without
standardized techniques. The benefit of transdural ICG VA re-
mains highly questionable, as established techniques such as
intraoperative neuronavigation already offer accurate transdural
visualization of the meningioma. In total, 75% of all investigat-
ed cases benefitted from transdural imaging following ICGVA:
in the authors opinions, it increased the feeling of safety during
dural opening and assessing vessel patency. Data regarding
objective long-term follow-up of these Bpositive^ cases is lack-
ing. Authors claim arterial and venous imaging could address
the uncertainty of patency, anastomotic flow, and the distinction
between tumor draining veins and collateral ones. Its benefit
has been described in the minority of patients, without objecti-
fying criteria to determine superiority of this application above
surgery without this tool. Fluorescein fluorescence has been
performed with filter (filtered surgical microscopy) and without
(standard white light microscopy). Despite the convenience and
affordability of white light fluorescein surgical microscopy,
contrast between tumor and surrounding tissue is markedly less
evident compared to filtered surgical microscopy. Additionally,
one group [54] reported that the intraoperative fluorescein-
induced meningioma fluorescence did not significantly alter
the surgical strategy, emphasizing the questionability of this
fluorophore in meningioma surgery.
Differentiation between meningioma invasion and reactive
tissue is limited at present. Pre-operatively, changes of dura
mater and bone can be observed as a Bdural tail sign^ or bone
hypertrophy. The dural tail sign is often observed on MRI
scans as dural thickening adjacent to the meningioma, and is
either caused by meningioma invasion or by vascular
Neurosurg Rev
congestion, both accounting for approximately 50% of cases
[59]. 5-ALA fluorescence was observed in invaded and nor-
mal dura mater, reducing sensitivity (50%). Reports describ-
ing ICG fluorescence did not determine fluorescence status of
adjacent dura mater or histologically investigated dural inva-
sion [35]. Lastly, the dura mater always fluoresces after fluo-
rescein administration, thus making the ability to differentiate
between healthy dura mater and meningioma infiltration high-
ly questionable. This emphasizes the need for highly sensitive
and specific fluorescent dyes in meningioma surgery.
Similarly, distinction between (reactive) hyperostosis and tu-
mor invasion cannot always be readily made. Bone invasion has
been reported in 20–68% meningioma patients, primarily in the
presence of hyperostosis. Regardless, invasion has been de-
scribed in non-hyperostotic bone as well, in 10–40% of cases
[60, 61]. Indeed, all fluorescent (n= 21) and none of the non-
fluorescent (n= 18) bone presented meningioma invasion in one
study [28] applying 5-ALA. The only other dye showing bone
fluorescence was fluorescein; however, histological results were
not provided [54]. ICG bone fluorescence was not observed. In
addition to location, local invasion of bone and soft tissuesmakes
it a technical challenge to determine the tumor margin using
available surgical tools. Fluorescence-guided meningioma sur-
gery may be a helpful tool to increase the rate of resection,
especially in patients with complex meningiomas.
In summary, we reviewed the current experience of 5-
ALA, ICG, and fluorescein in meningioma surgery. In our
opinion, fluorescence-guided meningioma surgery should be
a reliable, highly specific, and sensitive technique. Despite
numerous studies reporting the use of fluorescent dyes, cur-
rently there is no evidence that these tools improve the radical
resection rate and long-term recurrence-free outcome in me-
ningioma surgery and no evidence exists that safety of surgery
increased due to application of these fluorescence techniques.
Future perspectives
Failure of currently available fluorescence techniques clearly
show the need for a highly meningioma-specific probe clearly
distinguishing the tumor margin from healthy tissue has be-
come apparent after analyzing current data in this review. We
propose the development and intraoperative use of targeted
tracers, which could be achieved by binding a meningioma-
specific peptide to a fluorescent dye, preferably near-infrared
due to increased penetration depth. First, this should be con-
firmed in in vitro cultures and subsequently in in vivo studies
withmice and human subjects. Asmeningiomas are usually of
dural origin, passage of the tracer through the blood-brain-
barrier should not be an issue. The use of molecular
fluorescent-guided surgery (MFGS) has been successful for
various tumor types, e.g., in ovarian carcinoma [62] and peri-
toneal metastases of colorectal carcinomas [63] targeting
αvβ3-integrin or folate receptor α and vascular endothelial
growth factor α, respectively. The use of MFGS seems feasi-
ble for the optimization of meningioma surgery, which is cur-
rently a high priority in our ongoing research.
Next to this, improving and validating existing fluorescence-
guided techniques could be an alternative. Current evidence is
mostly based on case reports and case series and therefore an
organized trial could be another next step. The organization of
such a trial could improve the quality of evidence tremendously
and is a necessary step in the further development of thisMFGS
technique. Outcome measures to be considered are among
others extent of resection, fluorescence status and homogeneity,
and correlation between fluorescence and WHO grade, along
with long-term follow-up.
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